SAN DIEGO, CA – Mindera Corporation announced that it has been invited to present Mind.Px, their flagship Precision Medicine test for predicting patient response to psoriasis biologics, at the 8th Annual Dermatology Summit. The Dermatology Summit is the premier national commercial dermatology conference and is timed to coincide annually with the J.P. Morgan Healthcare Conference.
Featured in the Summit’s “Entrepreneurial Company Showcase”, Tobin Dickerson, Ph.D., Chief Scientific Officer and Co-founder of Mindera, will be presenting Mind.Px, a test to predict patient response to expensive psoriasis biologics before prescription.
“We thank the organizers of the Dermatology Summit for the opportunity to present our work,” said Dr. Dickerson. “Providing physicians, patients, and payers critical baseline biomarker measurements correlated with clinical outcomes data will bring Personalized Medicine to the dermatology community. Proper pre-treatment choice of biologics will improve clinical outcomes while significantly lowering specialty drug costs to the overall healthcare system. We look forward to introducing Mind.Px to the dermatology community in 2021.”
Mind.Px is Mindera’s first application of its novel Precision Medicine platform for dermatology. Using Mindera’s proprietary FDA registered dermal biomarker patch, the Mindera platform allows for minimally invasive extraction of rich biomarker data from individual patient skin. Captured molecules are sent to the Mindera CLIA-certified lab for analysis. Using Machine Learning, these baseline biomarkers can be correlated to clinical outcomes data from psoriasis patients who received specific biologic drugs, resulting in continuous evolving and improving predictive analyses for personalized drug responses. Systemwide, predicting biologic responses using Mind.Px can result in both improved psoriasis patient outcomes and billions of dollars of annual cost avoidance to the healthcare system.
For more information on the Dermatology Summit, please visit dermsummit.com.
Mindera is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera is a CLIA certified Laboratory. Find out more at www.minderadx.com.